rv3-bb
Vaccineexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 15, 2018 (NCT03483116)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- RotavirusImmunity, active
Rotavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04344054 | Phase 2 | Sep 30, 2020 | Bill and Melinda Gates Foundation, Murdoch University, PATH, SK Bioscience Co., Ltd., University of Cincinnati |
| NCT03483116 | Phase 2 | Jun 15, 2018 | Murdoch University, Wellcome Trust |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Murdoch University | Academic/Hospital | 2 | 1 | 1 | 2018 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2020 |
| PATH | Academic/Hospital | 1 | 1 | 1 | 2020 |
| SK Bioscience Co., Ltd. | For profit | 1 | 0 | 1 | 2020 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Wellcome Trust | Academic/Hospital | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1